No Data
No Data
Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting
New Analyst Forecast: $NRIX Given $16.0 Price Target
Beyond The Numbers: 8 Analysts Discuss Nurix Therapeutics Stock
Leerink Partners Initiates Nurix Therapeutics(NRIX.US) With Hold Rating, Announces Target Price $16
Leerink Partners Initiates Coverage On Nurix Therapeutics With Market Perform Rating, Announces Price Target of $16
Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia